A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular ...

Weight-loss jabs, such as Ozempic and Wegovy, have revolutionised the way we treat obesity in humans, and scientists now want ...

GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...

The executives of the companies say by pairing weight-loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) with ...

For Elizabeth Honigsberg, a general and bariatric surgeon and obesity and weight management specialist at Dartmouth Hitchcock Medical Center in Lebanon, combating obesity and the misconceptions that s ...

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by ...